Hepatocyte growth factor (HGF) and its receptor MET have been implicated in uterine development, pregnancy, and endometrial disorders, such as endometriosis and carcinoma. In vitro studies have shown that HGF acts as a mitogen, motogen, and morphogen on endometrial epithelial cells. However, the expression and regulation of HGF and MET in the uteri of different species remain obscure. The present study aimed to investigate the changes of HGF, MET, and HGF activator (HGFA) expression in the uterine endometrium during the estrous cycle in mice and to explore estrogen and progesterone regulation of their expression. MKI67 immunostaining was conducted to examine the association between HGF/MET expression and endometrial cell proliferation. Endometrial epithelial and stromal cells both expressed HGF, HGFA, and MET, but the cell type-specific patterns changed during the cycle. Estrogen and progesterone differentially regulated HGF, MET, and HGFA expression. Progesterone up-regulated their expression in the stroma and down-regulated their expression in the luminal epithelium, whereas 17-beta-estradiol down-regulated their expression in the glandular epithelium. The pattern of HGF/MET overall correlated with that of MKI67. In conclusion, HGF, HGFA, and MET expression in mouse uterus changes during the estrous cycle in a stage-, cell type-, and compartmentspecific manner under the influence of estrogen and progesterone. HGF likely plays a role in cyclic endometrial remodeling, such as cell proliferation via autocrine/paracrine mechanisms in mouse uterus.
INTRODUCTION
Hepatocyte growth factor (HGF) is a multifunctional growth factor that displays remarkable mitogenic, motogenic, morphogenic, and antiapoptotic activities in a variety of cells, mainly through its receptor MET tyrosine kinase. Data from Hgf transgenic mice indicate that overexpression of HGF leads to abnormal development and tumor formation [1] . Previous studies have implicated HGF in multiple processes, including trophoblast cell proliferation during implantation [2] , uterine epithelial cell morphogenesis during pregnancy [3] , postnatal development [4] and in vitro cell culture [5] , and progression of endometrial cancer [6] and endometriosis [7] .
Despite the importance of HGF and MET in uterine function, the regulation of their expression in the uteri of different species remains obscure. The dogma is that HGF is a stromal-derived growth factor in the endometrium, where it functions in a paracrine way through MET in the epithelial cells. However, HGF protein has been localized to both normal human endometrial epithelium and endometrial carcinoma cells [8] . In cycling or pregnant ovine uterus, HGF mRNA is expressed in the endometrial stroma, with higher levels in the stratum compactum of the intercaruncular endometrium, whereas MET mRNA is expressed exclusively in the luminal and glandular epithelium (GE) [9] . The variations of their abundance in ovine uterus during the estrous cycle and pregnancy suggest complex actions of ovarian steroids and/or cytokines. A more recent study revealed an up-regulation of MET mRNA in the GE in ovine endometrium by progesterone (P 4 ) [10] . Lindsey and Brenner [11] reported that HGF mRNA levels are regulated by estrogen and P 4 in primate endometrium, but those authors did not provide any information on its cell type-specific changes. In pregnant mice, Hgf mRNA is primarily localized to the mesometrial deciduas during Embryonic Days 6.5-8.5, whereas MET protein is present in trophoblast cells [2] . Yang and Park [12] demonstrated that Met mRNA is present in the luminal epithelium of mouse endometrium, but those authors did not specify the estrous stage of the uterus. Yang and Park also detected mouse uterine Hgf mRNA by PCR analysis but failed to localize it by in situ hybridization (ISH) because of the low expression levels. The cyclic changes of HGF and MET expression in mouse uterus and the regulation by ovarian steroids remain unknown.
Secreted as a single-chain zymogen, HGF is cleaved between Arg 494 and Val 495 to generate a biologically active, disulfide-linked heterodimer [13, 14] . Several potential activators for HGF have been identified that include HGF activator (HGFA), factor XIIa, MT-SP1/matriptase, hepsin, urokinasetype plasminogen activator, and tissue-type plasminogen activator [15] [16] [17] [18] [19] [20] [21] . Among them, HGFA exhibits the most potent activity in processing pro-HGF to active HGF [22] . HGFA is produced as an inactive zymogen, the nucleotide sequence of which is homologous to that of coagulation factor XII [19] , and it can be activated by thrombin [23] . In addition to the liver, which produces the highest level of HGFA, this protease is also expressed in the kidney [24] , brain [25] , placenta [26] , gastrointestinal tract [27] , synovial tissue [28] , and hair follicles [29] . Accumulated evidence indicates that HGFA plays an important role in organogenesis, tissue repair, and tumor growth through activating pro-HGF [30] [31] [32] [33] [34] [35] . HGFA has been detected in human placental villi and membranes as well as in the decidual cells, suggesting its role in the activation of pro-HGF at these sites [26] , but the hormonal regulation of HGFA and its message during pregnancy are unknown. The expression and regulation of HGFA and its message in cycling uterus have not been reported in any species.
The present study was designed to characterize the expression profiles of HGF, MET, and HGFA and their mRNAs in the uterus during the estrous cycle in mice and to explore estrogen and P 4 regulation of their expression. In addition, MKI67 immunostaining was conducted to examine the association between HGF/MET expression and endometrial cell proliferation.
MATERIALS AND METHODS

Animals and Steroid Hormone Treatments
CFR/CD1 female mice (age, 8-12 wk) were utilized for all studies. Mice were purchased from Harlan and housed within environmentally controlled conditions under the supervision of a licensed veterinarian. All animal procedures were approved by the University of Kansas Medical Center Institutional Animal and Use Committee. Mice were maintained on a 14L:10D photoperiod and provided water and mice chow ad libitum.
Vaginal smears were used to stage the estrous cycle [36] . Mice exhibiting normal estrous cycles were killed at proestrus, estrus, metestrus, or diestrus between 0900 and 1300 h. To investigate the effects of ovarian steroids, 8-wkold female mice were ovariectomized and rested for 14 days. Mice were then primed with two daily s.c. injections (Day 1 and Day 2) of 100 ng of 17-betaestradiol (E 2 ; Sigma) in sesame seed oil before the experiment [37, 38] . On Day 8, groups of three mice were killed by cervical dislocation at 2, 4, 8, and 24 h after one of the following treatments: 1) no treatment (Veh), 2) 4 days (Days 5-8) of daily s.c. injections of 1 mg of P 4 in 0.1 ml of sesame seed oil (P 4 ), 3) one (Day 8) s.c. injection of 50 ng of E 2 in 0.1 ml of sesame seed oil (E 2 ), 4) 4 days (Days 5-8) of daily s.c. injections of 1 mg of P 4 with one s.c. injection of 50 ng of E 2 at the same time as the last P 4 injection (PþE). The hormonal treatment strategy is well-established and has been used to recapitulate the cell-cycle kinetics of the estrous cycle and early pregnancy [37, 38] . To examine whether the estrogen and P 4 regulation of the HGF system is mediated via their corresponding nuclear receptors, mice were injected s.c. with the estrogenreceptor antagonist ICI-182,780 (Tocris Cookson, Inc.; 500 lg/mouse; dissolved in 100% ethanol and resuspended in sesame oil; one injection 30 min before E 2 treatment) or the P 4 -receptor antagonist RU486 (Mifepristone; Tocris Cookson, Inc.; 500 lg/mouse; dissolved in 100% ethanol and resuspended in sesame oil; four daily injections 30 min before P 4 treatment) before hormonal treatments for 8 or 24 h. Uteri were removed, snap-frozen in liquid nitrogen, and stored at À808C until utilized for protein or RNA extraction. For immunohistochemistry and ISH, the middle half of the uterine horn was prepared.
Real-Time Quantitative RT-PCR
Real-time quantitative RT-PCR (qPCR) analysis was carried out as previously described [39] . Total RNA was extracted from frozen uteri using TRIzol reagent. Complementary DNAs were synthesized from 2 lg of total 1038 ZHANG RNA using Maloney murine leukemia virus reverse transcriptase and random hexamer primers. The resulting cDNAs were diluted 1:10 in sterile water, and 1-ll aliquots were used in the qPCR reactions. Primers used were as follows:
0 and 1887R5 0 -CATCGCGGGACCAACTGT-3 0 . The qPCR was carried out on an Applied Biosystems HT7900 Sequence Detector. A notemplate reaction was included during each experiment to control for DNA contamination. Amplification of 18S rRNA (with Eukaryotic 18S rRNA Endogenous Control, catalog no. 4310893E; AB Applied Biosystems) was used to normalize the level of mRNA expression. The conditions for the real-time qPCR reactions were 508C for 2 min (one cycle), 958C for 10 min (one cycle), 958C for 15 sec and 608C for 1 min (40 cycles). A standard curve was run in each assay, with an arbitrary value assigned to the highest standard and corresponding values to the subsequent dilutions. Each cDNA sample was run in triplicate. The relative abundance of each target was normalized against that of 18S rRNA.
In Situ Hybridization
In situ hybridization was performed as previously described [40] . Briefly, the middle half of the right uterine horn was excised and embedded in O.C.T. tissue freezing medium (Sakura Fineteck U.S.A., Inc.) and snap-frozen on dry ice. Cryostat sections (thickness, 10 lm) were placed on Fisherbrand Superfrost Plus slides and stored at À808C until utilized. The cRNA probes were synthesized using the PCR method and digoxigenin (DIG) labeling [41] . Primers were designed incorporating T7 or T3 RNA polymerase promoters in the 5 0 end of the primers. DIG-labeled antisense and sense cRNA probes were made by in vitro transcription using the MAXIscript T7/T3 transcription kit (catalog no. 1326; Ambion) and DIG-11-UTP (catalog no. 11209256910; Roche). Prehybridization was performed at 688C for 1 h in the hybridization mixture (50% formamide, 53 SSC [13 SSC: 0.15 M sodium chloride and 0.015 M sodium citrate], and 120 lg/ml of salmon sperm DNA). After denaturing the probes for 5 min at 808C, hybridization was performed at 688C for 1 h and then cooled to 428C for 20 h. Slides were then treated with 20 lg/ml of RNase A for 30 min at 378C. After washing in 0.53 SSC for 30 min at 428C and then in 0.53 SSC for 30 min at room temperature, hybridization signals were detected using an anti-DIG-alkaline phosphatase antibody (catalog no. 11093274910; Roche). The color development was achieved by incubation with 20 ll/ml of BCIP/ NBT stock solution (catalog no. 11681451001; Roche), 100 mM NaCl, 50 mM MgCl 2 (pH 9.5), and 0.1 M levamisole for 48 h at room temperature in the dark.
Western Blot Analysis
Total protein content was extracted from frozen uteri using radioimmunoprecipitation assay buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 1 mM ethylenediaminetetra-acetic acid, and 0.1% SDS) containing a protease/phosphatase inhibitor cocktail (0.1 mg/ml PMSF, 30 ll/ml of aprotinin, 5 lg/ml of leupeptin, and 1 mM sodium orthovanadate; Sigma). Protein concentrations were determined using the DC Protein Assay (Bio-Rad Laboratories). Thirty-five micrograms of proteins were subjected to 4-12% Bis-Tris (Invitrogen) gel electrophoresis and electroblotted onto polyvinylidene fluoride membranes (Invitrogen). After blocking with 5% nonfat dry milk in Tris-buffered saline Tween-20 (50 mM Tris-HCl, 150 mM NaCl, and 0.05% Tween-20, pH 7.5) for 2 h at room temperature, blots were incubated with 0.2 lg/ml of goat-anti-mouse HGF-a (AF2207; R&D Systems) or 0.6 lg/ml of goat-anti-HGFA-L (N-19, sc-1371; Santa Cruz Biotechnology, Inc.) overnight at 48C. On the second day, blots were washed and incubated with rabbit-anti-goat-HRP (Jackson ImmunoResearch Laboratories, Inc.) for 1 h at room temperature. Blots were then washed and immunodetection conducted using an enhanced chemiluminescence (ECL) kit (Amersham Biosciences). Next, blots were stripped and reprobed for b-actin using goatanti-b-actin (I-19, sc-1616; Santa Cruz Biotechnology). The expression level of each protein was normalized to the level of b-actin.
Immunohistochemistry
Uterine specimens fixed in 10% neutral buffered formalin and embedded in paraffin wax (section thickness, 5 lm) were deparaffinized with xylene and rehydrated with a graded series of ethanol. Antigen retrieval was conducted using antigen-unmasking solution (H-3300; Vector Laboratories, Inc.). Sections were incubated in 3% H 2 O 2 in water for 10 min for quenching of endogenous peroxidase activity. Immunohistochemistry was carried out using the VECTASTAIN elite ABC Kits (PK6105 for goat IgG and PK6101 rabbit IgG; Vector Laboratories, Inc.). After blocking with appropriate normal serum, sections were incubated with primary antibodies overnight at 48C. On the second day, slides were washed and incubated with appropriate secondary antibodies for 30 min at room temperature. Slides were then incubated with ABC reagents for 30 min at room temperature, stained with a diaminobenzidine substrate kit (SK-4100; Vector Laboratories, Inc.), and briefly counterstained with hematoxylin. Primary antibodies used were as follows: goat-anti-HGFA-L (1 lg/ml, N-19, sc-1371; Santa Cruz Biotechnology), rabbit-anti-HGFa (0.5 lg/ml, 18281; IBL Co.), rabbit-anti-MET (0.125 lg/ml, sc-162; Santa Cruz Biotechnology), and goat-anti-MKI67 (0.06 lg/ml, M-19, sc-7846; Santa Cruz Biotechnology). Substitution of the primary antibodies with appropriate polyclonal IgG was used as a negative control. Mouse lung or kidney was used as a positive control.
Statistical Analysis
All data were analyzed using SPSS Version 13.0 software (SPSS, Inc. 
, SC adjacent to the LE; SC2, SC adjacent to the MSC; À, negative; þ/À, marginal; þ, low; þþ, moderate; þþþ, high.
indicated statistical significance, post hoc analysis was made using the Tukey honestly significant difference procedure. Significance was set at P , 0.05 for all comparisons.
RESULTS
HGF and Hgf
Cycling uteri. HGF protein was primarily localized to glandular and luminal epithelial cells as well as stromal cells (SC) in cycling uteri (Fig. 1 , A-E, and Table 1 ). HGF immunoreactivity was observed in SC adjacent to the luminal epithelium (LE) at diestrus and proestrus, whereas minimal stromal staining was observed at estrus and metestrus. A marked decrease in HGF immunoreactivity in GE and a marked increase at the apical side of the LE were observed at estrus. Faint HGF expression was also detected in myometrial smooth muscle cells (MSC) across the estrous cycle (data not shown). In the lung (Supplemental Fig. S1 ; all supplemental Western blot analysis demonstrated that HGF protein was in mature form across the cycle. Uterine HGF protein levels were high at proestrus, drastically decreased at estrus, remained low at metestrus, and increased again at diestrus stage (Fig. 2) .
The ISH analysis revealed an expression pattern of Hgf mRNA similar to that of HGF protein (Fig. 3 , A-E, and Table  2 ). Stromal staining was observed in SC adjacent to the LE at diestrus and proestrus but not at estrus and metestrus. At estrus, Hgf mRNA expression was decreased in the GE and increased in LE. Please note that some nonspecific signals were caused by lipid vesicles in and around the LE on some sections (these nonspecific signals were not observed at estrus stage or after estrogen treatment).
The qPCR analysis indicated that steady-state levels of Hgf mRNA paralleled those of HGF protein in cycling uterus (Fig.  4A) .
Steroid-treated uteri. Immunohistochemistry showed that uterine HGF protein (Fig. 1, F -O, and Table 1 and Supplemental Fig. S2 ) was primarily localized to LE and GE in the Veh group. P 4 decreased HGF expression in the LE and induced it in the SC adjacent to the LE. E 2 decreased HGF staining in the epithelial cells of some, but not all, endometrial glands and induced a shift of luminal epithelial HGF protein to the apical surface at 24 h. The HGF staining in the GE without 
STEROIDAL REGULATION OF UTERINE HGF SYSTEM a lumen remained high in the 24-h E 2 group. In the PþE group, the HGF staining was decreased in both GE and LE but increased in SC adjacent to the LE at 24 h as compared to the Veh group. Compared with P 4 alone, cotreatment with E 2 and P 4 decreased HGF staining intensity in the GE. Faint HGF expression was also detected in the MSC in each treatment group without apparent differences. Pretreatment with ICI-182,780 or RU486 blocked the effects of E 2 and P 4 , respectively, at 24 h. The ISH analysis revealed that Hgf mRNA expression pattern was consistent with that of HGF protein in steroidtreated uteri (Fig. 3 , F-J, and Table 2 ). P 4 induced subepithelial stromal Hgf mRNA expression but decreased its expression in the LE. Hgf mRNA expression was decreased in some of the endometrial glands at 24 h in the E 2 group. In the PþE group, Hgf mRNA expression was decreased in all the glands.
The qPCR analysis (Fig. 4B ) demonstrated that Hgf steadystate mRNA levels were increased by P 4 but decreased by E 2 . In addition, E 2 inhibited/reversed P 4 -induced up-regulation of Hgf mRNA.
HGFA and Hgfac
Cycling uteri. The expression of HGFA protein was primarily localized to the GE, LE, glandular lumen, and the SC adjacent to the LE (Fig. 5 , A-E, and Table 3 ). HGFA immunoreactivity in the GE was highest at proestrus and lowest at estrus and metestrus. Luminal epithelial expression of HGFA was slightly increased at the apical side at estrus. At 
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ZHANG diestrus and proestrus, HGFA was also present in SC adjacent to the LE. Minimal staining was observed in the MSC. In the kidney, HGFA immunoreactivity was observed in the epithelial cells of proximal and distal convoluted tubules (Supplemental Fig. S3 ). Western blot analysis detected HGFA protein at 34 kDa, which represents the active form of this protease. No significant differences in HGFA protein levels were observed in homogenized uteri (Fig. 6) .
Hgfac mRNA expression was assessed by ISH (Fig. 7 , A-E, and Table 4 ). At proestrus, Hgfac mRNA was primarily localized to the GE, SC adjacent to the LE, and to a lesser extent, LE. At estrus, its expression was increased in the LE but decreased in GE and disappeared in SC. At metestrus, Hgfac mRNA expression levels in LE and GE were similar. At diestrus, Hgfac mRNA reappeared in the SC adjacent to the LE.
The qPCR analysis (Fig. 8A) revealed that uterine Hgfac steady-state mRNA levels were low at diestrus and proestrus. As estrus, Hgfac mRNA levels were increased by 20-fold (P , 0.01) as compared to proestrus.
Steroid-treated uteri. HGFA protein (Fig. 5 , F-O, and Table 3 and Supplemental Fig. S4 ) was localized to the endometrial LE and GE, with higher intensity on the apical surface in ovariectomized mice (Veh group). In the P 4 group, HGFA in LE was evenly distributed in the cells instead of on the apical side. P 4 also induced HGFA expression in the SC adjacent to the LE. The HGFA expression after E 2 treatment was similar to that in the Veh group at 24 h. Compared with P 4 alone, cotreatment with E 2 and P 4 decreased HGFA immunoreactivity in the GE at 24 h. At 8 h, E 2 , either alone or used with P 4 , also induced HGFA staining in the SC adjacent to the myometrium (Supplemental Fig. S4 ). Pretreatment with ICI-182,780 or RU486 blocked the effects of E 2 and P 4 , respectively, at 24 h (Fig. 5, F-O ) and 8 h (Supplemental Fig. S4 ).
The ISH revealed that Hgfac mRNA was primarily localized to the GE and LE in the Veh groups. After E 2 treatment for 24 h, its abundance in the LE was significantly increased. P 4 induced its expression in the SC adjacent to the LE and decreased it in the LE. Compared with P 4 alone, cotreatment with E 2 and P 4 decreased Hgfac mRNA expression in the GE at 24 h (Fig. 7, F-J) . At 8 h (Supplemental Fig. S5 ), E 2 , either used alone or with P 4 , did not significantly affect Hgfac expression as compared to the Veh or P 4 group.
The qPCR analysis revealed that E 2 induced an increase in total uterine Hgfac steady-state mRNA levels at 24 h (P , 0.05). P 4 alone showed no significant effects on total uterine Hgfac mRNA levels, but pretreatment with P 4 blocked E 2 -upregulation of Hgfac mRNA (Fig. 8B ).
MET and Met
Cycling uteri. Overall, the expression of MET protein in the cycling uteri showed a pattern similar to that of HGF (Fig. 9 , A-E, and Table 5 ). MET immunoreactivity was decreased in the GE but increased in the LE, especially on the apical surface at estrus. At diestrus and proestrus, SC adjacent to the LE was also positively stained for MET. Faint staining for MET was also observed in MSC and endothelial cells in the myometrium across the estrous cycle, with no significant variations. In the lung, MET immunoreactivity was observed in airway epithelia (Supplemental Fig. S6) .
The ISH analysis revealed that cellular expression pattern of Met mRNA was consistent with that of MET protein (Fig. 10 , A-E, and Table 6 ). At estrus, Met mRNA expression was decreased in the GE but increased in the LE. Stromal staining was observed in the SC adjacent to the LE at diestrus and proestrus but not at estrus and metestrus.
The qPCR analysis demonstrated that Met mRNA levels showed moderate variations across the estrous cycle (Fig.  11A) . Highest Met mRNA levels were shown at estrus. At diestrus and proestrus, total uterine Met mRNA levels were roughly one third of those at estrus (P , 0.05).
Steroid-treated uteri. Uterine MET protein was primarily localized to endometrial GE and LE in the Veh group. P 4 decreased MET expression in the LE but induced it in the SC adjacent to the LE. E 2 did not significantly affect MET expression. However, compared with P 4 alone, cotreatment with E 2 and P 4 decreased MET expression in the GE at 24 h. As compared to the Veh group, cotreatment with E 2 and P 4 decreased MET expression was decreased in both the GE and the LE but induced in the SC at 24 h. Low levels of MET were also detected in the MSC of uteri from each treatment group without apparent differences. Pretreatment with ICI-182,780 or RU486 blocked the effects of E 2 and P 4 , respectively, at 24 h (Fig. 9, F -O, and Table 5 and Supplemental Fig. S7 ). The ISH analysis revealed that Met mRNA expression pattern agreed with MET protein in steroid-treated uteri. P 4 induced subepithelial stromal Met mRNA expression but decreased its expression in the LE. Compared with P 4 alone, cotreatment with E 2 and P 4 decreased Met mRNA expression in the GE at 24 h (Fig. 10 , F-J, and Table 6 ).
The qPCR analysis revealed that E 2 had no significant effect on total uterine Met mRNA levels, whereas P 4 or cotreatment with E 2 and P 4 slightly but significantly decreased Met mRNA levels (Fig. 11B) .
MKI67
Cycling uteri. MKI67 immunohistochemistry was conducted as a marker of cell proliferation. Results showed that MKI67 was primarily localized to the GE, LE, as well as SC in cycling uteri (Fig. 12) . At diestrus and proestrus, nuclear MKI67 staining in SC was primarily localized to those adjacent to the LE. At estrus, although some MKI67-positive nuclei were randomly distributed throughout the stroma, the number of positively stained SC adjacent to the LE was markedly reduced. At metestrus, few SC were positively stained for MKI67. Moreover, nuclear MKI67 expression was decreased in the GE at estrus as compared to diestrus and proestrus.
DISCUSSION
Findings from the present study indicate a cell type-and compartment-specific regulation of the uterine HGF system by   FIG. 9 . Immunohistochemistry of MET protein expression in cycling uteri (A-E) and steroid-treated uteri (F-O): A) proestrus; B) estrus; C) metestrus; D) diestrus; E) diestrus, negative control; F, Veh, 24 h; G) E 2 , 24 h; H) P 4 , 24 h; I) PþE, 24 h; J) P 4 , 24 h, negative control; K) E 2 plus ICI-182,780 (ICI), 24 h; L) P 4 plus RU486 (RU), 24 h; M) PþE plus ICI, 24 h; N) PþE plus RU, 24 h; O) E 2 plus ICI, 24 h, negative control. Arrowhead indicates positive immunostaining. ge, glandular epithelium; le, luminal epithelium; s, stroma. Original magnification 3400. 
1044 ZHANG E 2 and P 4 during the estrous cycle. Serum E 2 and P 4 levels vary across the estrous stages. E 2 levels are highest at estrus, whereas P 4 levels are highest at diestrus [42, 43] . The increase in HGF, HGFA, and MET expression in the SC adjacent to the LE at diestrus appears to be a P 4 response. The increase in LE expression of HGF and MET at estrus appears to be the result of decreased P 4 levels. The increase in LE Hgfac mRNA expression at estrus perhaps results from both decreased P 4 and increased E 2 levels. LE expression of HGFA protein only showed a slight increase at the apical side at estrus. Western blot analysis failed to show any differences in HGFA protein levels in homogenized uteri across the cycle. The reason for the disparity between HGFA protein and mRNA is not understood. One possible explanation is that the luminal epithelial cells release HGFA into the uterine lumen. This is supported by the demonstration of HGFA immunostaining in the lumen of some glands, especially at proestrus and estrus. Alternatively, posttranscriptional and/or posttranslational modifications may be involved in the regulation of uterine HGFA expression. It is equally possible that there are some isoforms of HGFA or its precursor in the mouse uterus that the antibody used in the 
, SC adjacent to the LE; SC2, SC adjacent to the MSC; À, negative; þ/À, marginal; þ, low; þþ, moderate; þþþ, high. present study failed to interact in immunostaining and Western blot analysis. The decrease in HGF, MET, and HGFA expression in the GE at estrus appears to be an E 2 response, but P 4 priming is necessary for E 2 to fully exert its effects. Pretreatment with ICI-182,780 or RU486 blocked the effects of E 2 and P 4 , respectively, indicating that the hormonal effects are mediated through their cognate nuclear receptors. The co-ordinated and sequential actions of estrogen and P 4 direct uterine tissue remodeling during estrous cycling while preparing for a receptive endometrium for blastocyst implantation. The dynamic hormonal regulation of the HGF system in the mouse uterus likely plays a critical role in uterine remodeling during both the estrous cycle and pregnancy by constantly altering endometrial anatomy and physiology in a cell type-and compartment-specific manner. HGF-induced disruption of epithelial cell junctions and increase in paracellular permeability are implicated in the dissociation of cancer cells [44] . At diestrus, increased HGF expression in the GE would likely increase the permeability of cell junctions, leading to increased secretion of histotroph nutrients required for peri-implantation blastocyst development. Junctional complex integrity plays a role in trophoblast attachment to the LE [45] . The P 4 down-regulation of HGF expression in the LE would theoretically facilitate preimplantation embryo attachment on the LE. Treatment of pregnant animals in the preimplantation stage with RU486 blocks implantation [46] . It would be interesting to examine if the effect of RU486 in blocking the P 4 -induced decrease in HGF expression in the LE contributes to this phenomenon.
The pattern of glandular epithelial cell proliferation differs from that of luminal epithelial cells [47] . During the estrous cycle, luminal epithelial cell proliferation does not significantly change, but the glandular epithelial cell proliferation is significantly decreased at estrus [48] (present study). Wood et al. [43] reported that circulating P 4 levels inversely correlated with uterine luminal epithelial proliferation but that E 2 levels inversely correlated with glandular proliferation in cycling uteri. The present study showed a positive correlation between HGF/MET expression and MKI67 immunoreactivity in the mouse endometrium during the estrous cycle. Because HGF is a well-known mitogen, it seems reasonable to postulate that HGF/MET may be involved in the compartment-specific regulation of endometrial cell proliferation by ovarian steroid hormones. The compartment-specific effects of the estrous cycle on the expression of the uterine HGF system are most probably caused not only by levels of E 2 and P 4 but also by their compartment-specific effects on the expression of estrogen and P 4 receptors [48] .
The cellular expression of HGF and MET in the endometrium seems to be both species-specific and developing stage-specific. The differences in their expression patterns between the mouse and the sheep are interesting and, perhaps, are related to the different implantation schemes. Although Met mRNA was previously localized only to mouse endometrial luminal epithelial cells [12] , those authors did not specify the estrous stage of the uterus. Based on the morphology, it was most likely at estrus. As shown in the present study, Met mRNA was primarily localized to endometrial epithelial cells at estrus, with much higher intensity in the LE than in the GE. 
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The origin of HGF mRNA in human endometrium remains elusive. Although HGF protein has been localized to both epithelial cells and SC in human endometrium in vivo, Sugawara et al. [5] failed to detect HGF mRNA expression in isolated human endometrial epithelial cells. Data from the present study indicate that both endometrial epithelial cells and SC have the capacity to express HGF and MET proteins and their mRNAs in murine uterus. Epithelial localization of HGF/ Hgf mRNA in other organs has been reported previously [49] [50] [51] [52] . The concept that HGF is a stromal-derived growth factor is mainly based upon in vitro cell culture studies. It is noteworthy that the cell type-specific expression pattern of HGF may change during in vitro cell culture [53] .
Hepatocyte growth factor is not only a mitogen but also a motogen and a morphogen. In the present study, a gradient of HGF concentration in both the LE and the SC was noted. The role of this gradient is not clear at this point, but a few possibilities exist. During tissue repair after injures, increased HGF expression is found at the leading edge of the epithelial cells, which triggers epithelial cell migration and, thus, healing of the epithelium. At estrus, increased HGF expression was observed at the edge of the LE, suggesting a potential role for HGF in luminal epithelial cell migration and reorganization. It is also possible that the gradient of HGF in the stroma may function as a chemoattractant and induce cell migration in the stroma toward the LE.
The expression of HGFA protein, but not its mRNA, has recently been shown in the rat ovary [54] . The murine uterus, however, is capable of synthesizing both HGFA protein and its mRNA. Although the present study does not show any direct evidence of HGF activation by HGFA in the mouse uterus, the correlation between the expression pattern of HGFA and those of HGF/MET suggests that HGFA perhaps play a role in uterine HGF activation. Interestingly, increased HGFA protein expression was observed in the stroma at 8 h following E 2 treatment, whereas no parallel up-regulation of Hgfac mRNA was observed. The E 2 induction of stromal HGF expression was blocked by ICI-182,780 pretreatment, indicating a nuclear estrogen receptor effect. This up-regulation is not likely to result from either de novo synthesis or release from the epithelial cells. Most likely, it results from infiltration from the bloodstream. The liver produces the highest amount of pro-HGFA and releases it into the plasma. Estrogen has been shown to induce uterine uptake of plasma proteins, such as albumin, plasminogen, and prothrombin [55, 56] . In cycling uteri, HGFA is not expressed in the stroma adjacent to the myometrium. HGFA expression in peri-implantation uteri has not been examined. As such, it is currently unknown whether the up-regulation of HGFA protein in the stroma by E 2 at 8 h has any physiological association.
In summary, data obtained from the present study provide, to our knowledge, the first evidence that HGF, HGFA, and MET expression in mouse uterus changes during the estrous cycle in a stage-, cell type-, and compartment-specific manner under the influence of estrogen and P 4 . The findings provide a foundation for further investigation on the role of the HGF system in mediating hormonal regulation of uterine biology.
